By Guest Blogger | Published: September 2, 2014
Source
The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in combination for the treatment of chronic infection in adults.
The company will now start negotiations with each of the national pricing and reimbursement authorities in the EU countries where it wants to launch the product—and those negotiations will be conducted amid the turbulence created by arguments over the price for Gilead’s Sovaldi (sofosbuvir).
For the full Applied Clinical Trials article by Peter O’Donnell, click here.
This entry was posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory and tagged Bristol Myers Squibb, Daklinza, directly-acting antiviral, EC, EU, Gilead, Sovaldi. Bookmark the permalink. Trackbacks are closed, but you can post a comment.
The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in combination for the treatment of chronic infection in adults.
The company will now start negotiations with each of the national pricing and reimbursement authorities in the EU countries where it wants to launch the product—and those negotiations will be conducted amid the turbulence created by arguments over the price for Gilead’s Sovaldi (sofosbuvir).
For the full Applied Clinical Trials article by Peter O’Donnell, click here.
This entry was posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory and tagged Bristol Myers Squibb, Daklinza, directly-acting antiviral, EC, EU, Gilead, Sovaldi. Bookmark the permalink. Trackbacks are closed, but you can post a comment.
No comments:
Post a Comment